Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

Group 1 - Zoetis (ZTS) stock decreased by 2.02% to $122.41, underperforming the S&P 500, which fell by 0.84% [1] - Prior to the recent trading session, Zoetis shares had declined by 3.42%, lagging behind the Medical sector's gain of 0.16% and the S&P 500's gain of 1.8% [1] Group 2 - The upcoming earnings report for Zoetis is scheduled for February 12, 2026, with projected earnings per share (EPS) of $1.4, indicating no change from the same quarter last year [2] - Revenue is estimated to be $2.37 billion, reflecting a 2.08% increase compared to the same quarter of the previous year [2] Group 3 - For the full year, analysts expect earnings of $6.34 per share and revenue of $9.45 billion, representing changes of +7.09% and 0%, respectively, from last year [3] Group 4 - Recent adjustments to analyst estimates for Zoetis are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] Group 5 - Changes in estimates are directly related to stock price performance, and the Zacks Rank system incorporates these changes to provide a rating system [5] Group 6 - Zoetis currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 18.36, which is a premium compared to the industry average Forward P/E of 17.2 [6] Group 7 - The company has a PEG ratio of 2.16, while the Medical - Drugs industry has an average PEG ratio of 1.15 [7] - The Medical - Drugs industry is ranked 159 in the Zacks Industry Rank, placing it in the bottom 36% of over 250 industries [7] Group 8 - The Zacks Industry Rank evaluates the strength of industry groups based on the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [8]